7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Paraneoplastic Syndromes D010257 4 associated lipids
Periapical Diseases D010483 4 associated lipids
Periapical Granuloma D010484 3 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Pericardial Effusion D010490 2 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Periodontal Diseases D010510 15 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Periostitis D010522 1 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Polycythemia Vera D011087 13 associated lipids
Prediabetic State D011236 1 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Prenatal Exposure Delayed Effects D011297 2 associated lipids
Progeria D011371 3 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Prosthesis Failure D011475 1 associated lipids
Radicular Cyst D011842 2 associated lipids
Rheumatic Fever D012213 1 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Root Resorption D012391 2 associated lipids
Rupture, Spontaneous D012422 1 associated lipids
Sarcoma, Ewing D012512 2 associated lipids
Osteosarcoma D012516 50 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Sclerosis D012598 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomatitis D013280 14 associated lipids
Synovitis D013585 15 associated lipids
Synovitis, Pigmented Villonodular D013586 1 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Temporomandibular Joint Disorders D013705 4 associated lipids
Thinness D013851 11 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Tinnitus D014012 4 associated lipids
Tooth Migration D014085 2 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Resorption D014091 1 associated lipids
Uremia D014511 33 associated lipids
Urologic Neoplasms D014571 2 associated lipids
Vascular Diseases D014652 16 associated lipids
Vision Disorders D014786 10 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Wounds and Injuries D014947 20 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Younes A and Aggarwall BB Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. 2003 Cancer pmid:12879461
Liu JZ et al. [Expression of human osteoprotegerin gene in E. Coli and bioactivity analysis of expression product]. 2003 Zhonghua Wai Ke Za Zhi pmid:14680558
Nawroth P et al. [Osteoporosis and cardiovascular disease--two sides of the same coin?]. 2003 Med. Klin. (Munich) pmid:12928809
Yamada Y et al. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. 2003 Mol. Genet. Metab. pmid:14680982
Nakatsuka K et al. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. 2003 J. Bone Miner. Res. pmid:12929927
Li JP and Ling JQ [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. 2003 Zhonghua Kou Qiang Yi Xue Za Zhi pmid:12930661
Schett G et al. The role of osteoprotegerin in arthritis. 2003 Arthritis Res. Ther. pmid:12932284
Stilgren LS et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 Calcif. Tissue Int. pmid:14667132
Karsdal MA et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. 2003 J. Biol. Chem. pmid:12933809
Okada T et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 Clin. Exp. Metastasis pmid:14669795
Benevolenskaia LI [Issues of osteoporosis in present-day medicine]. 2003 Vestn. Akad. Med. Nauk SSSR pmid:12934464
Gannagé-Yared MH et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. 2003 J. Endocrinol. Invest. pmid:14669830
Sugatani T et al. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. 2003 J. Cell. Biochem. pmid:12938156
Ashcroft AJ et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. 2003 Immunity pmid:14670302
Min JK et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. 2003 J. Biol. Chem. pmid:12893832
Chong B et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. 2003 J. Bone Miner. Res. pmid:14672344
Teitelbaum SL and Ross FP Genetic regulation of osteoclast development and function. 2003 Nat. Rev. Genet. pmid:12897775
Nielsen KL et al. Biglycan deficiency interferes with ovariectomy-induced bone loss. 2003 J. Bone Miner. Res. pmid:14672350
Si AI et al. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. 2003 J. Cell. Biochem. pmid:12898514
Nitta K et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. 2003 Am. J. Kidney Dis. pmid:12900812
Fizazi K et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. 2003 Clin. Cancer Res. pmid:12855635
Okuma K et al. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. 2003 J. Virol. pmid:12857926
Padigel UM et al. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. 2003 J. Immunol. pmid:14607948
Gruber HE and Rude RK Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. 2003 Biotech Histochem pmid:14989640
Terpos E et al. New insights into the pathophysiology and management of bone disease in multiple myeloma. 2003 Br. J. Haematol. pmid:14632767
Ha H et al. Lipid rafts are important for the association of RANK and TRAF6. 2003 Exp. Mol. Med. pmid:14508068
Zhang L et al. The role of calmodulin in the regulation of osteoclastogenesis. 2003 Endocrinology pmid:12960067
Abrahamsen B et al. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. 2003 Calcif. Tissue Int. pmid:12384814
Sezer O et al. RANK ligand and osteoprotegerin in myeloma bone disease. 2003 Blood pmid:12424190
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Smith MD et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. 2003 Ann. Rheum. Dis. pmid:12634226
Sakurai A et al. Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. 2003 Infect. Immun. pmid:14500523
Kim HH et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. 2003 FASEB J. pmid:14500543
Nakamura M et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. 2003 Endocrinology pmid:14500574
Zhang Z et al. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. 2003 J. Immunol. pmid:14500659
Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. 2003 Clin. Chem. pmid:14633883
Jung K et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. 2003 J. Urol. pmid:14634401
Su X et al. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. 2003 Zhonghua Nei Ke Za Zhi pmid:14636471
Takayanagi H [Crosstalk between the immune and skeletal system]. 2003 Ryumachi pmid:14598653
Ha H et al. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. 2003 J. Biol. Chem. pmid:12637570
Cho TJ et al. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. 2003 Arthritis Rheum. pmid:14558090
Ritchlin CT et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 2003 J. Clin. Invest. pmid:12639988
von Tirpitz C et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. 2003 Eur J Gastroenterol Hepatol pmid:14560148
Kido S et al. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. 2003 Bone pmid:12810169
Barillé-Nion S and Bataille R New insights in myeloma-induced osteolysis. 2003 Leuk. Lymphoma pmid:14565645
Kudlacek S et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. 2003 Bone pmid:12810175
Mandelin J et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 J Bone Joint Surg Br pmid:14653607
Ikeda T et al. Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. 2003 Pathol. Int. pmid:12828610
Malyszko J et al. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. 2003 Transplant. Proc. pmid:14529897
Crotti T et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. 2003 J. Periodont. Res. pmid:12828654
Ren W et al. Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. 2003 Biomaterials pmid:14530078
Tazoe M et al. Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. 2003 Arch. Oral Biol. pmid:12828991
Wiethe C et al. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. 2003 J. Immunol. pmid:14530334
Wiethe C et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. 2003 J. Immunol. pmid:12626542
Wagner EF and Matsuo K Signalling in osteoclasts and the role of Fos/AP1 proteins. 2003 Ann. Rheum. Dis. pmid:14532157
Ueland T et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. 2003 J. Clin. Endocrinol. Metab. pmid:12629078
Ueland T et al. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. 2003 Bone pmid:14555269
Schoppet M et al. Increased osteoprotegerin serum levels in men with coronary artery disease. 2003 J. Clin. Endocrinol. Metab. pmid:12629080
Han W et al. Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. 2003 Biotechnol. Appl. Biochem. pmid:12630898
Koshihara Y et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. 2003 J. Endocrinol. pmid:12630919
Alvarez L et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. 2003 Arthritis Rheum. pmid:12632438
Bord S et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. 2003 Bone pmid:12633785
Nimmanapalli R and Bhalla K Targets in apoptosis signaling: promise of selective anticancer therapy. 2003 Methods Mol. Biol. pmid:12777745
Cheung J et al. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. 2003 J. Endocrinol. pmid:12773123
Nakamura H et al. Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. 2003 J. Med. Dent. Sci. pmid:12968638
Viereck V et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. 2003 J. Clin. Endocrinol. Metab. pmid:12970288
Yamagami H et al. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. 2003 Biochem. Pharmacol. pmid:12948861
Srivastava S et al. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. 2003 J. Biol. Chem. pmid:12952963
Lee HA et al. Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. 2003 Exp. Physiol. pmid:12955156
Yorke R et al. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. 2003 Eur. J. Cancer pmid:12957466
Kaneyama K et al. Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. 2003 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:12973279
Lee ZH and Kim HH Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. 2003 Biochem. Biophys. Res. Commun. pmid:12745060
Boyle WJ et al. Osteoclast differentiation and activation. 2003 Nature pmid:12748652
Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. 2003 Blood pmid:12689925
Zheng B et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. 2003 Blood pmid:12689928
Fujita D et al. Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12711253
Katavić V et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. 2003 J. Immunol. pmid:12538719
Clohisy D Cellular mechanisms of osteolysis. 2003 J Bone Joint Surg Am pmid:12540662
Vanderkerken K et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. 2003 Cancer Res. pmid:12543775
Yu Q et al. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. 2003 J. Immunol. pmid:12574344
Rifas L et al. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. 2003 J. Cell. Biochem. pmid:12577299
Gordeladze JO and Reseland JE A unified model for the action of leptin on bone turnover. 2003 J. Cell. Biochem. pmid:12577304
Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. 2003 J. Immunol. pmid:12594294
Kato I et al. TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 Eur. J. Immunol. pmid:12548564
Sordillo EM and Pearse RN RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 Cancer pmid:12548579
Oyajobi BO and Mundy GR Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. 2003 Cancer pmid:12548580
Croucher PI et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. 2003 Cancer pmid:12548581
Lipton A Bisphosphonates and metastatic breast carcinoma. 2003 Cancer pmid:12548585
Liu JZ et al. [The OPG/RANKL/RANK system and bone resorptive disease]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15971575
Liu JZ et al. [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15969033
Nishimura K et al. Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. 2003 Hum. Cell pmid:15147042
Choi BK et al. Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 Infect. Immun. pmid:12496170
Liu D et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. 2003 Int. J. Mol. Med. pmid:12469211
Chagraoui H et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. 2003 Blood pmid:12506018
Lee Y et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. 2003 J. Orthop. Res. pmid:12507581
Sabokbar A et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. 2003 J. Orthop. Res. pmid:12507582
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Crotti TN et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. 2003 J. Rheumatol. pmid:14677171
Helfrich MH Osteoclast diseases. 2003 Microsc. Res. Tech. pmid:12879419

Table of Content